No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
KRYS240517C250000
- 0.87
- 0.000.00%
15min DelayClose May 17 10:19 ET
0.00High0.00Low
0.87Open0.87Pre Close0 Volume348 Open Interest250.00Strike Price0.00Turnover3062.99%IV52.88%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.87Time Value100Contract SizeAmericanOptions Type0.0556Delta0.0028Gamma188.62Leverage Ratio-91.5217Theta0.0000Rho10.49Eff Leverage0.0015Vega
Intraday
- 5D
- 1D
News
Krystal Biotech to Present at the American Thoracic Society 2024 International Conference
PITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new p
Krystal Biotech Price Target Maintained With a $200.00/Share by HC Wainwright & Co.
Krystal Biotech Price Target Maintained With a $200.00/Share by HC Wainwright & Co.
Krystal Biotech to Present at BofA Securities 2024 Health Care Conference
PITTSBURGH, May 08, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the
Krystal Biotech Reveals Eye Treatment Vector at ARVO 2024
Krystal Biotech Inc (KRYS) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth and ...
Krystal Biotech's Battle to Scale VYJUVEK Production Amid Regulatory Hurdles and Soaring Demand
Comments
The strong revenue growth is mirrored in the share price gain. Despite the strong run, top performers like Krystal Biotech can continue winning for decades. The stock's recent performance improvement may suggest real business momentum.
Investing in Krystal Biotech (NASDAQ:KRYS) Five Years Ago Would Have Delivered You a 389% Gain 1
High insider ownership at Krystal Biotech implies management's alignment with shareholders. Yet, no insider transactions in the last three months and significant share selling over the past year are concerning.
Analysts' optimism soars as they forecast Krystal Biotech to break even soon, given its massive projected annual growth rate of 68%. The firm's debt-free operation, unusual in loss-making biotech companies, lowers investment risk.
Market rewards Krystal Biotech's significant revenue growth despite recent stock price decline. Bullish sentiment suggests ongoing positive trend, irrespective of the current drop.
Despite the substantial selling of shares over the past year, insiders' ownership is still considerable. However, the lack of recent insider purchases could be of concern. Investors are advised to also consider the potential risks facing Krystal Biotech.
1
Read more